ERBB2 and breast carcinoma: From the 20 matched patient samples analysed (Figure 2C), EGR4-S was detected in 80% of all HER2+ breast cancer tissues and none of the matched control tissues (with a difference in proportion between cancer and normal breast tissue of 0.80 (95% CI 0.62, 0.98), p < 0.001).